Journal: Acta Histochemica et Cytochemica

Article Title: Intracellular Localization of PD-L1 in Rab10-positive Open Tubular Endosome System of Cancer Cells

doi: 10.1267/ahc.25-00060

Figure Lengend Snippet: Dimerized PD-L1 by BMS-202 treatment was internalized into early endosomes and delivered to lysosomes. HeLaM cells co-expressing GFP-PD-L1 and mCherry-Rab5 or mCherry-Lgp120 were treated with BMS-202. ( A ) GFP-PD-L1, which was localized to the cell surface, Rab10-positive tubules, and Rab10-negative small vesicles in HeLaM cells at 0 min, was internalized into Rab5-positive early endosomes 30 min after BMS-202 treatment. ( B ) After120 min, GFP-PD-L1 accumulated in perinuclear vesicles. Some of these are mCherry-Lgp120-positive lysosomes. Bars = 10 μm.

Article Snippet: BMS-202 (PD-1/PD-L1 inhibitor 2) was purchased from Selleck Biotech (Yokohama, Japan).

Techniques: Expressing

Journal: Acta Histochemica et Cytochemica

Article Title: Intracellular Localization of PD-L1 in Rab10-positive Open Tubular Endosome System of Cancer Cells

doi: 10.1267/ahc.25-00060

Figure Lengend Snippet: Expression of mCherry-CMTM6 retains PD-L1 on the cell surface and tubules even after BMS-202 treatment. HeLaM cells co-expressing GFP-PD-L1 and mCherry-CMTM6 were treated with BMS-202. In cells overexpressing CMTM6, GFP-PD-L1 was predominantly observed on the membranes of cell surface and Rab10-positive tubules even after BMS-202 treatment. Bars = 10 μm.

Article Snippet: BMS-202 (PD-1/PD-L1 inhibitor 2) was purchased from Selleck Biotech (Yokohama, Japan).

Techniques: Expressing

Journal: Frontiers in Pharmacology

Article Title: Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy

doi: 10.3389/fphar.2026.1740903

Figure Lengend Snippet: (A) Principle of the reporter assay for anti-PD-1/PD-L1 inhibitors; (B) Activities of PP-1 and BMS-202 in the PD-1/PD-L1 NFAT reporter model. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, One-way analysis of variance (ANOVA).

Article Snippet: The virtual screening results and corresponding activity data of the prioritized compounds are summarized in , with BMS-202 (CAS No.: 1675203–84-5, IC 50 = 25 nM), developed by Bristol-Myers Squibb (BMS), serving as the positive control in the HTRF assay.

Techniques: Reporter Assay